← boothcheck

CAI vs LH stock comparison

CARIS LIFE SCIENCES, INC. vs LABCORP HOLDINGS INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

The split here is simple: Labcorp is diagnostics as infrastructure, a national lab network earning a 10.8% operating margin with a 6.2% free-cash yield and a dividend at 24.1 times earnings; Caris is diagnostics as frontier, molecular tumor profiling at a 2.4% operating margin priced at 52.9 times. Labcorp carries acquisition debt, 0.73 turns; Caris carries IPO cash, a 7.05 current ratio. Returns on equity run 10.8% against 5.7%. The network's price asks for continuation and pays you cash while it continues; the frontier's price asks for transformation and pays nothing until it arrives. Both can deliver; only one has to.

Comparison updated 2026-07-10.

CAI vs LH: the numbers

MetricCAILH
Price$18.52$271.48
Market cap$5.2B$22.5B
SectorMedical DiagnosticsMedical Diagnostics
StageGrowthMature
Implied growth (priced in)-1.3%
P/E52.924.1
P/B8.822.58
P/S5.771.59
EV/EBITDA37.217.3
Revenue growth+91.2%+7.4%
Gross margin28.7%
Operating margin2.4%10.8%
Net margin3.8%6.7%
Return on equity5.7%10.8%
Return on assets2.9%4.9%
Return on invested capital8.8%7.5%
FCF yield2.4%6.2%
Dividend yield1.1%
Debt / equity0.640.73
Current ratio7.051.73
Altman Z (solvency)4.142.88
Piotroski F (quality)5 / 94 / 9
Full CAI report → Full LH report →
Get boothcheck's read on CAI and LH, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.